Dishman Carbogen Amcis logo

Dishman Carbogen Amcis share price

NSE: DCALBSE: 540701Pharmaceuticals & BiotechnologySmall Cap

Dishman Carbogen Amcis Limited · Face value ₹2 · Listed Sep 2017
Last close ₹147.70up ₹8.86 (6.38%)BSE ₹147.65

Share price at the NSE close on 27 Oct 2026. Previous close ₹138.84.

27 Oct: open ₹138.84, high ₹149.65, low ₹138.60

52-week range of traded prices to 27 Oct 2026
₹128.50Low, 30 Mar 2026₹303.00High, 31 Oct 2025
Market cap
₹2,316 Cr979th largest listed
P/E
143.30
P/E without one-offs
121.88
P/B
0.35
Dividend yield
Nonein the last 12 months
ROE
0.3%
ROE without one-offs
0.3%
ROCE
1.4%
Debt to equity
0.42
Volume, NSE
1,99,46540.3% delivered

Dishman Carbogen Amcis share price chart

Daily closes since Sep 2017, adjusted for splits and bonuses

−49.7%over a year · Nifty 500 −8.8%

Results20-session average 1,66,392 shares a day, 54.9% delivered

Results

Consolidated; ₹ crore.Dishman Carbogen Amcis quarterly results

Revenue growth, 12 months
+0.2%
Net profit growth, 12 months
−84.5%

Quarter to Jun 2026, against the quarter before

Revenue
₹678 Crdown 20.41%
Net profit
−₹58 CrQuarter to Mar 2026: ₹22 Cr
Net margin
−8.5%

Revenue by quarter

₹789 CrSep 24₹682 CrDec 24₹716 CrMar 25₹708 CrJun 25₹653 CrSep 25₹720 CrDec 25₹851 CrMar 26₹678 CrJun 26
Peak revenue ₹851 Cr, quarter to Mar 2026; lowest ₹653 Cr, quarter to Sep 2025

Net profit by quarter, a loss in red

  • Net profit
  • Loss
₹33 CrSep 24₹4.63 CrDec 24₹43 CrMar 25₹23 CrJun 25₹65 CrSep 25−₹13 CrDec 25₹22 CrMar 26−₹58 CrJun 26
A loss in the quarter to Jun 2026, −₹58 CrA loss in 2 of the 8 quarters shown
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue789682716708653720851678
Net profit335432365−1322−58
Net margin4.2%0.7%6.0%3.3%10.0%−1.8%2.6%−8.5%
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.

Business segments

In the year to Mar 2026 the company reports one business segment which carries all its revenue.

Valuation

Today, against the company's own history.Dishman Carbogen Amcis PE ratio and valuation

Price to earnings

At or below today's level on 83% of 247 trading days over the last year.

LowestHighest
Its median28.66Industry median28.32
Price to book

At or below today's level on 20% of 1,976 trading days since Nov 2018.

LowestHighest
Its median0.48Industry median2.99
Dividend yield

At or below today's level on 89% of 2,236 trading days since Oct 2017.

LowestHighest
Its median0.00%Industry median0.50%

Where the return came from

Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.

OverReturn a yearEarnings growthChange in P/EDividend yield
1 year−40.3%+2,861.9%−98.0%0.0%
3 years+1.4%––0.0%
5 years+3.6%––0.0%
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2025.

Shareholding

Per cent of the company's shares, from the filing for Sep 2026.Dishman Carbogen Amcis shareholding pattern

Shareholding by group

  • Promoters59.32%
  • Foreign institutions6.97%
  • Indian institutions1.66%
  • Individuals and others32.06%
Holder
Adimans Technologies LLPPromoter59.32%
Mukul Mahavir AgrawalResident individuals, over ₹2 lakh at face value5.50%
Massachusetts Institute of TechnologyForeign portfolio investors, category I2.28%
Hbm Healthcare Investments (Cayman) LtdForeign portfolio investors, category II2.19%
Tejas TrivediResident individuals, over ₹2 lakh at face value1.00%
Holders are named in the company's own words: an insurer's holding can carry one of its funds' names. Mutual funds are left out here and listed fund by fund below.

Promoters have pledged 8.39% of their shares. Since Jun 2026: promoters unchanged, foreign institutions +0.11 pts, Indian institutions −0.41 pts, mutual funds unchanged.

Mutual fund holdings

4 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 3 of the 3 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.

Added
2
Cut
1
Held unchanged
1
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.

Promoter and insider buying and selling

Trades made since 28 Oct 2025.Dishman Carbogen Amcis insider trading

No promoter, director, key manager or employee bought or sold on the market.

  • Promoters and promoter group: no market trade · 4 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.

Dishman Carbogen Amcis competitors and peers

Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Dishman Carbogen Amcis in market cap.Healthcare companies

Where the company sits among the companies nearest its size

Return on equity across, P/E up, size is market cap
Company
Shukra Pharmaceuticals logoShukra PharmaceuticalsSHUKRAPHAR3,14587.2535.00+115.0%+256.2%47.2%47.3%0.01%
Solara Active Pharma Sciences logoSolara Active Pharma SciencesSOLARA3,07283.162.14+27.3%–2.7%6.4%0.00%
Hikal logoHikalHIKAL2,489–2.08−5.4%−153.4%−2.7%3.5%0.30%
Fredun Pharmaceuticals logoFredun PharmaceuticalsFREDUN2,452–8.82–––18.8%0.02%
Beta Drugs logoBeta DrugsBETA2,15139.784.91––16.4%14.2%0.00%
Sai Parenterals logoSai ParenteralsSAIPARENT2,113–4.31––––0.00%
Sakar Healthcare logoSakar HealthcareSAKAR2,07048.295.98+48.0%+119.8%13.2%16.6%0.00%
Indoco Remedies logoIndoco RemediesINDOCO2,03763.771.99+10.8%–3.2%1.8%0.09%
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.

Dividends

Per share, by the year it was paid for, and the latest payments.Dishman Carbogen Amcis dividend history

Dividend per share, ₹, restated for later splits and bonuses

Mar 180.2Mar 19Mar 20Mar 21Mar 22Mar 23Mar 24Mar 25Mar 26
Highest ₹0.20 a share, year to Mar 2019.
Ex-dateTypePer share
12 Sep 2019Final₹0.20
Latest payments, as declared, by ex-date.

Latest announcements

Routine notices left out.Dishman Carbogen Amcis announcements

Dishman Carbogen Amcis share price by year

Each calendar year to 2025.Dishman Carbogen Amcis share price history

YearClose at year endChangeHighest closeLowest close
2025247.59−8.5%314.40183.42
2024270.48+58.2%301.53136.50
2023170.95+80.1%177.0082.10
202294.90−52.9%220.1085.15
2021201.55+45.2%253.20103.50
2020138.80+64.5%212.6048.45
201984.40−63.4%248.3072.10
2018230.55−29.1%390.05213.90
2017325.05–352.05278.50
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2017 is from its first session, 21 Sep 2017.

Recent sessions

The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.

DateOpenHighLowCloseAverage priceVolumeDelivery
26 Oct 2026137.24142.01135.65138.84139.032,22,54351.0%
23 Oct 2026140.40140.56133.71136.28135.821,33,18144.3%
22 Oct 2026142.10144.88138.41140.02141.051,95,39248.5%
21 Oct 2026145.80146.39140.41142.10143.201,80,75253.1%
19 Oct 2026150.00150.84145.20145.80146.9789,59862.0%
16 Oct 2026151.50151.50148.81149.83149.9586,10562.4%
15 Oct 2026153.04155.85150.10151.18152.2578,64158.3%
14 Oct 2026150.56155.12149.50153.04152.431,43,34735.2%
13 Oct 2026150.10151.41148.00150.56149.451,15,08854.8%
Prices in ₹ per share as traded, not adjusted.

Company details

Managing director
Arpit Janmejay Vyas
At the end of the quarter to Jun 2026
NSE symbol
DCAL
BSE code
540701
ISIN
INE385W01011
Industry
Pharmaceuticals & Biotechnology
CIN
L74900GJ2007PLC051338
Corporate identity number, the registrar of companies' code for it
Incorporated
2007
Registered office
Dishman Corporate House, lscon-Bopal Road, Ambli, Ahmedabad 380058, Gujarat
Share registrar
MUFG Intime India Pvt. Ltd
Keeps the register of shareholders and handles transfers and dividend payments